News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2021 Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data Yael L. Maxwell November 15, 2021
News Conference News AHA 2020 Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS Michael O'Riordan November 14, 2020
News Conference News AHA 2017 ‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18 Michael O'Riordan November 15, 2017
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
News Conference News AHA 2012 AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community Jason Kahn November 11, 2012
News Conference News ‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year November 16, 2011